Ask VialBase
Research

Semaglutide in Patients With Chronic Kidney Disease and Overweight or Obesity (FLOW) — VialBase Research

Trial Summary

This trial (potentially part of the FLOW program) evaluates semaglutide’s renoprotective effects in patients with CKD who are overweight or obese. Note: The larger FLOW trial (NCT03819153) already showed positive kidney outcomes with semaglutide 1.0 mg in diabetic CKD patients. This study may extend that investigation to broader CKD populations or different dosing.

Design

  • Type: Randomized, double-blind, placebo-controlled
  • Population: Adults with CKD (eGFR 25-75 mL/min) and BMI 27+
  • Arms: Semaglutide vs. placebo
  • Duration: Event-driven with long follow-up
  • Key measures: eGFR slope, albuminuria, kidney failure events, cardiovascular events

Key Outcomes

Trial is recruiting; no results available yet. The related FLOW trial showed a 24% reduction in kidney disease progression with semaglutide in T2D patients with CKD.

Significance for Peptide Research

Kidney disease is a major complication of metabolic syndrome and obesity. If semaglutide demonstrates renoprotective benefits independent of diabetes, it would further cement GLP-1 RAs as organ-protective agents across the cardiorenal-metabolic spectrum. This trial connects to the broader GLP-1 RA organ protection evidence base.

See Also